EP
CYCN icon

Eversept Partners’s Cyclerion Therapeutics CYCN Stock Holding History

Eversept Partners’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-18,598
Closed -$413K – 84
2022
Q1 		$413K Hold
18,598
– – 0.03% 82
2021
Q4 		$640K Hold
18,598
– – 0.04% 96
2021
Q3 		$1.14M Buy
+18,598
New +$1.22M 0.08% 94
2020
Q3 		– Sell
-12,383
Closed -$1.46M – 54
2020
Q2 		$1.46M Sell
12,383
-4,474
-27% -$374K 0.2% 54
2020
Q1 		$893K Buy
+16,857
New +$1.2M 0.22% 45
2019
Q3 		– Sell
-946
Closed -$217K – 60
2019
Q2 		$217K Buy
+946
New +$268K 0.06% 61

Other funds holding CYCN

SPC
Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.83B AUM 65.74% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TFS
TrustCore Financial Services Brentwood, Tennessee $1.14B AUM 13.32% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return

Eversept Partners's CYCN Position: Q2 2022 in Review

Eversept Partners sold out of Cyclerion Therapeutics (CYCN) in Q2 2022, closing a stake of 18,598 shares — an estimated $413K sold.

Eversept Partners first reported a position in CYCN in Q2 2019 and held it in 6 quarters. The position peaked at $1.46M in Q2 2020. 41 funds tracked by Wall St. Rank hold CYCN as of Q2 2022.

  • Eversept Partners reported no remaining Cyclerion Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Eversept Partners sold 18,598 Cyclerion Therapeutics shares in Q2 2022, an estimated $413K.
  • Eversept Partners first reported a position in Cyclerion Therapeutics in Q2 2019 and held it in 6 quarters.
  • Eversept Partners's Cyclerion Therapeutics position peaked at $1.46M in Q2 2020.
  • 41 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q2 2022.

Based on Eversept Partners's 13F filing for Q2 2022, filed 15 Aug 2022.